<p>/PRNewswire/ -- PANTHERx® Rare Pharmacy，作为个性化罕见疾病护理的患者接入和支持服务的可信赖领导者和创新者，宣布被大冢制药选为独家特药药房，负责分发 VOYXACT®，这是一种 APRIL（增殖诱导配体）抑制剂，适用于减少有进展风险的成人原发性免疫球蛋白 A 肾病（IgAN）患者的蛋白尿。该适应症已根据蛋白尿减少获得加速批准。目前尚未确定 VOYXACT 是否能在 IgAN 患者中长期减缓肾功能下降。</p>
<p>&#34;我们与大冢制药的合作始于 2018 年，我们很高兴能继续作为 VOYXACT 的独家特药药房，&#34; PANTHERx Rare Pharmacy 首席执行官 Bansi Nagji 表示。&#34;每位 IgAN 患者的旅程都是独特的，我们提供超个性化护理的方法也是如此。这种新疗法代表了进步，我们很荣幸能够帮助那些最需要它的人获得这种治疗。&#34;</p>
<p><strong>关于 PANTHERx Rare</strong> PANTHERx Rare 通过不断关注每位患者和每种疗法，使罕见疾病护理变得更加超个性化和不那么令人不知所措。PANTHERx 的专家与患者、开处方医生和制药合作伙伴建立深厚的个人关系，作为可信赖的倡导者，确保无缝合作和卓越护理。自 2011 年在宾夕法尼亚州匹兹堡的一个车库成立以来，PANTHERx 已成长为美国最大的独立罕见药房，利用成熟公司的资源，同时保持小公司的响应能力、创新和对细节的关注。</p>
<p>PANTHERx 在所有 50 个州和美国领土均持有执照，并且是第一家获得健康护理认证委员会（ACHC）和利用审查认证委员会（URAC）在罕见疾病领域双重认证的全国药房。PANTHERx 还八次获得享有盛誉的 MMIT 患者选择奖，以表彰患者满意度，包括 2025 年的荣誉。</p>
<p>欲了解更多信息，请发送电子邮件至 [email protected] 或访问 www.pantherxrare.com。</p>
<p><strong>关于免疫球蛋白 A 肾病</strong> 免疫球蛋白 A 肾病（IgAN），也称为伯杰病，是一种自身免疫性疾病，当 IgA 聚集在肾脏中时，会导致炎症和肾脏损伤。正常情况下，IgA 帮助身体抵抗感染，但过多的沉积抗体会损害肾小球（过滤血液的微小血管），导致血液和蛋白质漏入尿液，并造成肾单位（肾小球所在的过滤单元）的瘢痕。</p>
<p>IgAN 的可见症状可能包括因尿液中含血（血尿）而导致的粉红色或可乐色尿液（血尿）、因蛋白泄漏（蛋白尿）而产生的泡沫尿，以及因多余液体（水肿）而导致的腿部、脚和踝部肿胀。虽然 IgAN 的症状可能多年不出现，但并发症可能包括高血压、慢性肾病、肾病综合症和肾衰竭。</p>
<p>1. VOYXACT®（sibeprenlimab-szsi）处方信息。https://www.otsuka-us.com/media/static/VOYXACT-PI.pdf</p>
<p>2. IgA 肾病 - NIDDK。国家糖尿病和消化及肾脏疾病研究所。https://www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy#what。访问日期：2024 年 5 月 24 日。</p>
<p>3. Pennmedicine.org。发布于 2023 年。https://www.pennmedicine.org/conditions/iga-nephropathy。访问日期：2024 年 5 月 24 日。</p>
<p><strong>PANTHERx Rare 媒体联系人：</strong> Jennifer May</p>
<p>[email protected]</p>
<p>来源 PANTHERx Rare Pharmacy</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE4Jk5ld3NJdGVtSWQ9TkU1MDE4MyZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTgwODQ1UFJfTkVXU19VU1BSX19fX19ORTUwMTgz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE4Jk5ld3NJdGVtSWQ9TkU1MDE4MyZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTgwODQ1UFJfTkVXU19VU1BSX19fX19ORTUwMTgz"/></p>

大冢制药(ADR)

<p>PANTHERx Rare Pharmacy 被大冢制药（Otsuka）选中，独家配药 VOYXACT®（sibeprenlimab-szsi），这是一种旨在减少成人原发性免疫球蛋白 A 肾病（IgAN）患者蛋白尿的药物。自 2018 年以来的合作，突显了 PANTHERx 对个性化罕见疾病护理的承诺。VOYXACT® 已获得加速批准，用于其减少蛋白尿的效果，但其对 IgAN 患者肾功能的长期影响尚未确定</p>

<p>, /PRNewswire/ -- PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Otsuka as the exclusive specialty pharmacy to dispense VOYXACT®, an APRIL (A Proliferation Inducing Ligand) blocker, indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN.</p>
<div class="lb-trans"><p>/PRNewswire/ -- PANTHERx® Rare Pharmacy，作为个性化罕见疾病护理的患者接入和支持服务的可信赖领导者和创新者，宣布被大冢制药选为独家特药药房，负责分发 VOYXACT®，这是一种 APRIL（增殖诱导配体）抑制剂，适用于减少有进展风险的成人原发性免疫球蛋白 A 肾病（IgAN）患者的蛋白尿。该适应症已根据蛋白尿减少获得加速批准。目前尚未确定 VOYXACT 是否能在 IgAN 患者中长期减缓肾功能下降。</p>
</div><p>&#34;Our collaboration with Otsuka dates back to 2018, and we're excited to continue that commitment as the exclusive specialty pharmacy for VOYXACT,&#34; said Bansi Nagji, CEO, PANTHERx Rare Pharmacy. &#34;Each patient's journey with IgAN is unique, and so is our approach to providing hyper-personalized care. This new therapy represents progress, and we're honored to help make it accessible to the people who need it most.&#34;</p>
<div class="lb-trans"><p>&#34;我们与大冢制药的合作始于 2018 年，我们很高兴能继续作为 VOYXACT 的独家特药药房，&#34; PANTHERx Rare Pharmacy 首席执行官 Bansi Nagji 表示。&#34;每位 IgAN 患者的旅程都是独特的，我们提供超个性化护理的方法也是如此。这种新疗法代表了进步，我们很荣幸能够帮助那些最需要它的人获得这种治疗。&#34;</p>
</div><p><strong>About PANTHERx Rare</strong> PANTHERx Rare makes rare disease care more hyper-personalized and less overwhelming by focusing relentlessly on each patient and each therapy. PANTHERx experts develop deep personal relationships with patients, prescribers, and pharmaceutical partners, serving as trusted advocates to ensure seamless collaboration and exceptional care. Since its founding in a garage in Pittsburgh, PA in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S., leveraging established-company resources while maintaining small-company responsiveness, innovation, and attention to detail.</p>
<div class="lb-trans"><p><strong>关于 PANTHERx Rare</strong> PANTHERx Rare 通过不断关注每位患者和每种疗法，使罕见疾病护理变得更加超个性化和不那么令人不知所措。PANTHERx 的专家与患者、开处方医生和制药合作伙伴建立深厚的个人关系，作为可信赖的倡导者，确保无缝合作和卓越护理。自 2011 年在宾夕法尼亚州匹兹堡的一个车库成立以来，PANTHERx 已成长为美国最大的独立罕见药房，利用成熟公司的资源，同时保持小公司的响应能力、创新和对细节的关注。</p>
</div><p>PANTHERx is licensed in all 50 states and U.S. territories and was the first national pharmacy to achieve dual accreditations in rare disease from the Accreditation Commission for Health Care (ACHC) and Utilization Review Accreditation Commission (URAC). PANTHERx is also the eight-time winner of the prestigious MMIT Patient Choice Award for patient satisfaction, including the 2025 honor.</p>
<div class="lb-trans"><p>PANTHERx 在所有 50 个州和美国领土均持有执照，并且是第一家获得健康护理认证委员会（ACHC）和利用审查认证委员会（URAC）在罕见疾病领域双重认证的全国药房。PANTHERx 还八次获得享有盛誉的 MMIT 患者选择奖，以表彰患者满意度，包括 2025 年的荣誉。</p>
</div><p>For more information, please email [email protected] or visit www.pantherxrare.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请发送电子邮件至 [email protected] 或访问 www.pantherxrare.com。</p>
</div><p><strong>About Immunoglobulin A Nephropathy</strong> Immunoglobulin A Nephropathy (IgAN), also known as Berger disease, is an autoimmune disease that results when clumps of IgA are deposited in the kidneys, causing inflammation and kidney damage.2,3 Normally IgA helps the body to fight infections but too much of the deposited antibodies damage glomeruli (tiny blood vessels in the kidneys that filter blood) which causes blood and protein to leak in the urine and scarring of the nephrons (filtering units where the glomeruli are located).2,3</p>
<div class="lb-trans"><p><strong>关于免疫球蛋白 A 肾病</strong> 免疫球蛋白 A 肾病（IgAN），也称为伯杰病，是一种自身免疫性疾病，当 IgA 聚集在肾脏中时，会导致炎症和肾脏损伤。正常情况下，IgA 帮助身体抵抗感染，但过多的沉积抗体会损害肾小球（过滤血液的微小血管），导致血液和蛋白质漏入尿液，并造成肾单位（肾小球所在的过滤单元）的瘢痕。</p>
</div><p>Visible symptoms of IgAN may include pink or cola-colored urine due to blood in the urine (hematuria), foamy urine from protein leakage (proteinuria), and swelling in the legs, feet and ankles due to excess fluid (edema).2 While symptoms of IgAN may not appear for many years, complications can include high blood pressure, chronic kidney disease, nephrotic syndrome and kidney failure.2</p>
<div class="lb-trans"><p>IgAN 的可见症状可能包括因尿液中含血（血尿）而导致的粉红色或可乐色尿液（血尿）、因蛋白泄漏（蛋白尿）而产生的泡沫尿，以及因多余液体（水肿）而导致的腿部、脚和踝部肿胀。虽然 IgAN 的症状可能多年不出现，但并发症可能包括高血压、慢性肾病、肾病综合症和肾衰竭。</p>
</div><p>1. VOYXACT® (sibeprenlimab-szsi) Prescribing Information. https://www.otsuka-us.com/media/static/VOYXACT-PI.pdf</p>
<div class="lb-trans"><p>1. VOYXACT®（sibeprenlimab-szsi）处方信息。https://www.otsuka-us.com/media/static/VOYXACT-PI.pdf</p>
</div><p>2. IgA Nephropathy - NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy#what. Accessed May 24, 2024.</p>
<div class="lb-trans"><p>2. IgA 肾病 - NIDDK。国家糖尿病和消化及肾脏疾病研究所。https://www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy#what。访问日期：2024 年 5 月 24 日。</p>
</div><p>3. Pennmedicine.org. Published 2023. https://www.pennmedicine.org/conditions/iga-nephropathy. Accessed May 24, 2024.</p>
<div class="lb-trans"><p>3. Pennmedicine.org。发布于 2023 年。https://www.pennmedicine.org/conditions/iga-nephropathy。访问日期：2024 年 5 月 24 日。</p>
</div><p><strong>PANTHERx Rare Media Contact:</strong> Jennifer May</p>
<div class="lb-trans"><p><strong>PANTHERx Rare 媒体联系人：</strong> Jennifer May</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE PANTHERx Rare Pharmacy</p>
<div class="lb-trans"><p>来源 PANTHERx Rare Pharmacy</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE4Jk5ld3NJdGVtSWQ9TkU1MDE4MyZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTgwODQ1UFJfTkVXU19VU1BSX19fX19ORTUwMTgz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NE50183&amp;Transmission_Id=202512180845PR_NEWS_USPR_____NE50183&amp;DateId=20251218"/></p>

08:45 ET
			
			
				PANTHERx® Rare Selected by Otsuka to Dispense VOYXACT® (sibeprenlimab-szsi) for the Treatment of Primary Immunoglobulin A Nephropathy

PANTHERx® Rare 被 Otsuka Pharmaceutical 选中，负责分发 VOYXACT®（sibeprenlimab-szsi）用于治疗原发性免疫球蛋白 A 肾病